Bristol-Myers Squibb Company (BMY): Price and Financial Metrics


Bristol-Myers Squibb Company (BMY)

Today's Latest Price: $59.81 USD

0.59 (-0.98%)

Updated May 28 8:04pm

Add BMY to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

BMY Stock Summary

  • Bristol Myers Squibb Co's market capitalization of $136,666,461,202 is ahead of 98.99% of US-listed equities.
  • With a price/earnings ratio of 143.26, Bristol Myers Squibb Co P/E ratio is greater than that of about 96.48% of stocks in our set with positive earnings.
  • With a year-over-year growth in debt of 676.36%, Bristol Myers Squibb Co's debt growth rate surpasses 97.14% of about US stocks.
  • Stocks that are quantitatively similar to BMY, based on their financial statements, market capitalization, and price volatility, are LLY, AMGN, AZN, SNY, and ABBV.
  • Visit BMY's SEC page to see the company's official filings. To visit the company's web site, go to www.bms.com.
BMY Daily Price Range
BMY 52-Week Price Range

BMY Stock Price Chart More Charts


BMY Price/Volume Stats

Current price $59.81 52-week high $68.34
Prev. close $60.40 52-week low $42.48
Day low $59.68 Volume 14,977,900
Day high $60.98 Avg. volume 16,125,156
50-day MA $58.60 Dividend yield 2.98%
200-day MA $57.65 Market Cap 135.33B

Bristol-Myers Squibb Company (BMY) Company Bio


Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecules, and biologics in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; immunoscience; and cardiovascular. The company was founded in 1887 and is based in New York, New York.


BMY Latest News Stream


Event/TimeNews Detail
Loading, please wait...

BMY Latest Social Stream


Loading social stream, please wait...

View Full BMY Social Stream

Latest BMY News From Around the Web

Below are the latest news stories about Bristol Myers Squibb Co that investors may wish to consider to help them evaluate BMY as an investment opportunity.

Exscientia raises $60m Series C - UKTN (UK Tech News)

Exscientia, the world leading artificial intelligence (AI) drug discovery company, today announced it has raised $60 million in a Series C financing round. The financing round has been led by new investor Novo Holdings with existing investors – Evotec, Bristol Myers Squibb, and GT Healthcare Capital (through its LPs) – participating in the round. Robert Ghenchev, …

UK Tech News | May 26, 2020

EMA accepts Bristol Myers applications for blood cancer treatments (NYSE:BMY)

The European Medicines Agency (EMA) has accepted for review Bristol Myers Squibb's (NYSE:BMY) marketing applications for two blood disorder treatments. Und

Seeking Alpha | May 22, 2020

U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Pomalyst® (pomalidomide) for AIDS-Related and HIV-Negative Kaposi Sarcoma

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #AIDS--U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Pomalyst® (pomalidomide) for AIDS-Related and HIV-Negative Kaposi sarcoma

Business Wire | May 15, 2020

Baupost moves: Adds Alphabet, Facebook; exits Bristol Myers Squibb (NASDAQ:GOOG)

Seth Klarman’s hedge fund Baupost Group as of March 31 disclosed new positions in Alphabet (GOOG, GOOGL) and Facebook (NASDAQ:FB), each weighing almost 5%

Seeking Alpha | May 15, 2020

Bristol Myers Squibb and bluebird bio to Present Updated Positive Results from Pivotal KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma Patients at ASCO20

PRINCETON, N.J., & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BMY #ASCO20--BMS & bluebird bio to Present Updated Positive Results from Pivotal KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma Patients

Business Wire | May 13, 2020

Read More 'BMY' Stories Here

BMY Price Returns

1-mo -3.75%
3-mo 2.11%
6-mo 6.66%
1-year 36.15%
3-year 21.09%
5-year 6.28%
YTD -5.39%
2019 27.74%
2018 -12.90%
2017 7.71%
2016 -13.49%
2015 19.26%

BMY Dividends

Ex-Dividend DateTypePayout AmountChange
Loading, please wait...
View Full BMY Dividend History

Continue Researching BMY

Here are a few links from around the web to help you further your research on Bristol Myers Squibb Co's stock as an investment opportunity:

Bristol Myers Squibb Co (BMY) Stock Price | Nasdaq
Bristol Myers Squibb Co (BMY) Stock Quote, History and News - Yahoo Finance
Bristol Myers Squibb Co (BMY) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8903 seconds.